10-Q: OPKO Health Q3 2025: Strategic Divestitures & R&D Growth

OPKO Health reports Q3 2025 results, highlighting strategic asset sales, increased R&D investment, and a significant reduction in operating loss despite revenue declines in services and products.

Summary

• Total revenues for the three months ended September 30, 2025, decreased by 13% to $151.7 million from $173.6 million in the prior year period.
• Total revenues for the nine months ended September 30, 2025, decreased by 13% to $458.4 million from $529.5 million in the same period of 2024.
• Net income for the three months ended September 30, 2025, was $21.6 million, down from $24.9 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $(194.4) million, significantly wider than the $(67.3) million loss in the same period of 2024.
• Operating income for the three months ended September 30, 2025, increased significantly to $48.1 million from $14.2 million in the prior year period.
• Operating loss for the nine months ended September 30, 2025, narrowed to $(79.1) million from $(118.9) million in the same period of 2024.
• A gain on sale of assets of $101.6 million was recognized for the three and nine months ended September 30, 2025, related to the Oncology Transaction.
• Cash, cash equivalents, and restricted cash were $428.9 million as of September 30, 2025.
• Repurchased 24,327,844 shares of Common Stock for approximately $33.5 million during the nine months ended September 30, 2025.
• Completed the sale of BioReference's oncology diagnostics business to Labcorp for $192.5 million in cash, with potential for an additional $32.5 million in contingent consideration.
• ModeX entered a license and collaboration agreement with Regeneron Pharmaceuticals, including a $7.0 million upfront payment and potential milestones exceeding $1.0 billion.
• ModeX received a $12.5 million milestone payment from Merck for the first participant dosing in a Phase 1 EBV vaccine study.
• The BARDA Contract funding increased to $110.0 million, with a potential value of $205.0 million if all options are exercised.
• Completed privately negotiated exchange transactions for $159.2 million principal amount of 2029 Convertible 144A Notes for 121,437,998 shares of Common Stock and $63.5 million in cash.

Sentiment

Score: 5

Explanation: While the company reported a wider net loss for the nine-month period and declining revenues, the significant improvement in Q3 operating income, strategic asset sales, and new high-potential R&D collaborations (Regeneron, Merck, BARDA) provide a mixed outlook. The reduction in SG&A expenses indicates cost control, but increased R&D spending and substantial interest expenses weigh on profitability. The strong cash position is a positive, but ongoing litigation and the need for sustained positive cash flow remain concerns.

Positives

• Operating income for the three months ended September 30, 2025, increased by 238% to $48.1 million from $14.2 million in the prior year period.
• Operating loss for the nine months ended September 30, 2025, narrowed by 33% to $(79.1) million from $(118.9) million in the prior year period.
• Successfully completed the Oncology Transaction, generating $192.5 million in cash and potential for $32.5 million in performance-based contingent consideration.
• Revenue from transfer of intellectual property and other increased by 42% in Q3 2025 and 34% for the nine months, driven by the BARDA contract and NGENLA/Genotropin profit share/royalties.
• Rayaldee net product revenue increased by $1.7 million in Q3 2025 and $1.1 million for the nine months compared to the prior year periods.
• ModeX secured a new collaboration agreement with Regeneron Pharmaceuticals, including a $7.0 million upfront payment and potential milestones exceeding $1.0 billion.
• ModeX received a $12.5 million milestone payment from Merck for advancing an EBV vaccine candidate into a Phase 1 study.
• Increased BARDA Contract funding to $110.0 million, with a potential value of $205.0 million, supporting multispecific antibody development.
• Selling, General and Administrative (SG&A) expenses decreased significantly in both Diagnostics (56% in Q3, 36% for 9M) and Pharmaceuticals (14% in Q3, 12% for 9M) due to cost-reduction initiatives and divestitures.
• Maintained a strong cash position of $428.9 million as of September 30, 2025, which is believed to be sufficient for operations and debt service beyond the next 12 months.

Negatives

• Total revenues decreased by 13% in Q3 2025 and 13% for the nine months ended September 30, 2025, compared to the prior year periods.
• Net loss for the nine months ended September 30, 2025, significantly widened to $(194.4) million from $(67.3) million in the prior year period.
• Revenue from services decreased by 21.5% in Q3 2025 and 20.8% for the nine months, primarily due to the sale of BioReference's lab operations and lower clinical test volume in continuing operations.
• Revenue from products decreased by 3.7% in Q3 2025 and 3.8% for the nine months, mainly due to lower sales volume in international operations and unfavorable foreign exchange impacts.
• Interest expense significantly increased to $97.2 million for the nine months ended September 30, 2025, from $33.2 million in the prior year, primarily due to induced conversion expense and loss on extinguishment related to 2029 Convertible Notes.
• Other income (expense), net, shifted to a $28.9 million expense for the nine months ended September 30, 2025, from $128.8 million income in the prior year, largely due to the absence of significant gains from the GeneDx investment and the inclusion of inducement expense.
• Loss from investments in investees increased for the nine months ended September 30, 2025.
• Research and development expenses increased by 5% in Q3 2025 and 22.5% for the nine months, driven by ModeX's early-stage programs and BARDA collaboration, and higher employee-related expenses.

Risks

• A history of losses and may not generate sustained positive cash flow sufficient to fund operations and R&D programs.
• The need for, and ability to obtain, additional financing when needed on favorable terms, or at all.
• Adverse results in material litigation matters or governmental inquiries, including the Israel Tax Authority assessment of approximately $246 million.
• The inherent risks in developing, obtaining regulatory approvals for, and commercializing new, commercially viable and competitive products and treatments.
• Research and development activities may not result in commercially viable products, and earlier clinical results may not be reproducible or indicative of future results.
• May not generate or sustain profits or cash flow from laboratory operations or substantial revenue from NGENLA, Rayaldee, and other pharmaceutical and diagnostic products.
• The ability to manage changing operations, including integration challenges for acquired businesses.
• The products in the ModeX Therapeutics, Inc. R&D pipeline may not ultimately be commercialized.
• Currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than company products.
• The ability and distribution and marketing partners' ability to comply with regulatory requirements regarding the sales, marketing, and manufacturing of products and product candidates.
• The performance of third-party distribution partners, licensees, and manufacturers over which there is limited control.
• Changes in regulation and policies in the U.S. and other countries, including increasing downward pressure on healthcare reimbursement.
• Increased competition, including price competition.
• Success is dependent on the involvement and continued efforts of the Chairman and Chief Executive Officer, Dr. Phillip Frost.
• Changing relationships with payors, suppliers, and strategic partners.
• Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services.
• The ability to maintain reimbursement coverage for products and services, including Rayaldee and the 4Kscore test.
• Failure to timely or accurately bill and collect for services.
• Information technology systems may be subject to unauthorized tampering, cyberattack, or other data security or privacy incidents that could impact billing processes or disrupt operations.
• Failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients.
• Failure to establish, and perform to, appropriate quality standards to assure the highest level of quality in testing services.
• Failure to maintain the security of patient-related information.
• The ability to obtain and maintain intellectual property protection for products and defend intellectual property rights.
• The ability to operate business without infringing the intellectual property rights of others.
• The ability to attract and retain key scientific and management personnel.
• The risk that the carrying value of certain assets may exceed the fair value of the assets causing impairment of goodwill or other intangible assets, particularly for the Ireland reporting unit and diagnostics segment.
• The ability to comply with the terms of the 2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services.
• Failure to obtain and maintain regulatory approval for products and services outside the U.S.
• Legal, economic, political, regulatory, currency exchange, and other risks associated with international operations.
• Disruptions to operations, including impact on employees and business continuity, from recent conflicts in the Middle East.
• Unstable economic and market conditions may have adverse consequences on business and financial condition.
• Changes in personnel and funding for government agencies, including the FDA, could negatively impact business and financial condition.
• Current uncertainties about tariffs and their effects on trading relationships may affect costs for and availability of raw materials or contribute to inflation.

Future Outlook

Management believes current cash, cash equivalents, and restricted cash are sufficient to meet anticipated cash requirements for operations and debt service beyond the next 12 months. Future cash requirements depend on product approvals, commercial success of NGENLA and Rayaldee, BioReference's financial performance, acquisitions, R&D progress, clinical trial outcomes, regulatory approvals, intellectual property costs, competitive landscape, financing availability, market development, and outcomes of legal proceedings. The company anticipates further legislative activity and administrative guidance regarding Pillar Two Model Rules for global minimum tax.

Management Comments

• "We believe that the cash, cash equivalents and restricted cash on hand on September 30, 2025 are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months."
• "We intend to continue to draw under these lines of credit as needed."
• "We intend to exhaust all judicial remedies necessary to resolve the matter [Israel Tax Authority assessment], as necessary, which could be a lengthy process."
• "We generally have cooperated, and intend to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise."

Industry Context

The company operates in the diversified healthcare sector, with a focus on pharmaceuticals and diagnostics. Its pharmaceutical segment is advancing long-acting human growth hormone (NGENLA) through a partnership with Pfizer, and Rayaldee for chronic kidney disease. The diagnostics segment, BioReference, is undergoing strategic divestitures (oncology diagnostics to Labcorp) to streamline operations. ModeX Therapeutics, a subsidiary, is actively developing multi-specific immune therapies for cancer and infectious diseases, securing significant collaborations with Merck and Regeneron, aligning with broader industry trends in advanced biologics and vaccine development. The increased R&D investment reflects the competitive and innovation-driven nature of the pharmaceutical and biotechnology industries.

Comparison to Industry Standards

• The collaboration with Pfizer for NGENLA (Somatrogon) positions the company alongside a major pharmaceutical player in the growth hormone market, competing with existing daily somatropin injections.
• ModeX's collaborations with Merck for an EBV vaccine candidate and Regeneron for multispecific antibodies demonstrate engagement with leading pharmaceutical companies in cutting-edge therapeutic areas, indicating a competitive R&D pipeline in immuno-oncology and infectious diseases.
• The divestiture of BioReference's oncology diagnostics business to Labcorp reflects a trend of larger diagnostic players consolidating specialized testing services, allowing the company to focus on its core diagnostic offerings like the 4Kscore prostate cancer test.
• The BARDA contract for multispecific antibody development aligns with global public health initiatives to rapidly respond to emerging infectious diseases, including viral variants like COVID-19 and influenza, a critical area for government funding and industry focus.

Management Changes

Corporate Governance

Legal Proceedings

• The Israel Tax Authority (ITA) issued an assessment of approximately $246 million (including interest) against OPKO Biologics related to uncertain tax positions for the 2014 through 2020 tax years. The company is appealing this assessment, believing the issues are without technical merit, and intends to exhaust all judicial remedies.
• BioReference and the Texas Office of the Attorney General (TX OAG) entered into a settlement agreement in February 2025 for $4.2 million, resolving alleged violations of the Texas Medicaid Fraud Prevention Act from 2005-2023. The final payment was made in September 2025, with BioReference not admitting any wrongdoing.
• A Corporate Integrity Agreement (CIA) became effective on July 14, 2022, with the OIG-HHS, resolving an investigation into alleged fee-for-service claims to Federal Health Care Programs. BioReference is required to maintain compliance programs, provide training, establish policies, and engage an independent review organization for five years. Non-compliance could result in monetary penalties and exclusion from Federal Health Care Programs.
• The company is currently responding to Civil Investigative Demands (CIDs), subpoenas, payor audits, and document requests for various matters relating to its laboratory operations.
• Some pending or threatened proceedings may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material.
• The company periodically identifies and reports overpayments to Medicare, Medicaid, and third-party payors, with participation in voluntary disclosure protocols potentially leading to significant settlement obligations or enforcement action.

Related Party Transactions

• Paid a $105,000 filing fee to the Federal Trade Commission (FTC) in July 2025 in connection with filings made by the company and Dr. Phillip Frost (CEO) relating to his percentage equity ownership interest and potential future purchases of Common Stock.
• The son of one of the company's directors was hired at ModeX in July 2025.
• Leases office space from Frost Real Estate Holdings, LLC, a company beneficially owned by Dr. Phillip Frost, with amended lease payments ranging from approximately $91 thousand to $103 thousand per month.
• Issued and sold approximately $71.1 million aggregate principal amount of 2029 Convertible Affiliate Notes to Affiliate Purchasers (Frost Gamma Investments Trust, controlled by Dr. Phillip Frost, and Dr. Jane H. Hsiao) in January 2024, in exchange for $55.0 million of 2023 Convertible Notes and $16.1 million accrued interest.
• Dr. Frost, an Affiliate Purchaser, subsequently purchased 2029 Convertible Notes on the open market in September 2024.
• Entered an E-Commerce Distribution Agreement with NextPlat Corp in October 2023, in which Dr. Frost owns a 13% interest, for an OPKO Health-branded online storefront in China and other Asian platforms.
• Entered an Assignment and Assumption Agreement with Ruen-Hui Biopharmaceuticals, Inc. in May 2023, in which Dr. Hsiao owns more than a 10% interest, for an exclusive license agreement with Academia Sinica.
• Owns approximately 6% of Pharmsynthez, which is the largest and controlling shareholder of Xenetic, in which the company has a 3% ownership interest.
• Holds investments in Zebra (29% ownership), Niagen (0.04%), COCP (2%), NIMS (1%), Eloxx (1%), and LeaderMed (47%), considered related party transactions due to executive management's ownership interests and/or board representation.
• BioReference procures products and services from subsidiaries of Danaher Corporation (Beckman Coulter, Integrated DNA Technologies Inc., Leica Microsystems Inc.), where Dr. Elias Zerhouni (Vice Chairman and President) sits on Danaher's board. Payments totaled $1.8 million, $2.0 million, and $0.3 million, respectively, for the nine months ended September 30, 2025.
• Reimburses Dr. Frost for company-related use of an airplane owned by a company beneficially owned by Dr. Frost for out-of-pocket operating costs. No amounts were reimbursed or accrued for Q3 2025 or 9M 2025.

Stakeholder Impact

• **Shareholders:** Impacted by the stock repurchase program (potential for increased EPS, reduced dilution), the exchange of convertible notes for common stock and cash (dilution for some, debt reduction for others), and the overall financial performance (net loss, operating income improvement). Strategic collaborations and asset sales could drive long-term value.
• **Employees:** Affected by cost-reduction initiatives, particularly in the diagnostics segment, leading to lower employee headcount. New R&D collaborations (ModeX with Regeneron, BARDA) could create new opportunities.
• **Customers (Diagnostics):** BioReference's divestiture of oncology diagnostics to Labcorp means a change in service provider for those customers. Continuing operations in New York and New Jersey, and specialized tests like 4Kscore, remain.
• **Customers (Pharmaceuticals):** Continued availability of NGENLA (Somatrogon) through Pfizer and Rayaldee. New drug development through ModeX could lead to future therapeutic options.
• **Creditors:** Impacted by debt management activities, including the issuance of 2044 Notes and the repurchase/exchange of 2029 Convertible Notes. The company's cash position and ability to generate sustained positive cash flow are key for debt service.
• **Regulatory Bodies:** Ongoing engagement with SEC (filings), FTC (antitrust), OIG-HHS (CIA compliance), Israel Tax Authority (assessment appeal), and Texas OAG (settlement). Compliance and legal outcomes are significant.
• **Partners (Pfizer, Merck, Regeneron, BARDA, Labcorp, Entera, Nicoya, VFMCRP, NextPlat):** Strategic alliances are critical for product development, commercialization, and revenue generation, indicating a complex network of interdependencies.

Next Steps

• Continue development and commercialization of Somatrogon (hGH-CTP) with Pfizer.
• Further expand the pharmaceutical product pipeline through ModeX's portfolio of development candidates.
• ModeX to continue research, development, and clinical evaluation of multispecific antibodies based on MSTAR technology under the BARDA Contract, including a Phase 1 clinical trial for a next-generation SARS-CoV-2 antibody.
• ModeX and Regeneron to discover and develop multispecific antibodies for several therapeutic indications.
• Merck to fund and lead preclinical, clinical development, and commercialization activities for EBV vaccine candidates.
• Continue to evaluate the impacts of enacted and pending legislation to enact Pillar Two Model Rules in non-U.S. tax jurisdictions.
• Management to continue monitoring economic effects of tariffs and opportunities to mitigate related impacts.
• Continue to exhaust all judicial remedies necessary to resolve the Israel Tax Authority assessment.
• Continue to comply with obligations under the Corporate Integrity Agreement.
• Continue to respond to CIDs, subpoenas, payor audits, and document requests for various matters relating to laboratory operations.
• Continue to assess billing and coding practices and investigate non-compliance issues.
• Continue to make future purchases for inventory and other items under various purchase arrangements.

Key Dates

Recommendation

The filing presents a mixed financial picture. While the company achieved a significant improvement in Q3 operating income and strategically divested non-core assets, the nine-month net loss widened considerably due to substantial interest expenses and the absence of prior-year investment gains. New collaborations with Regeneron and Merck, along with increased BARDA funding, highlight promising R&D pipeline potential, but these are long-term plays. The company's strong cash position provides stability, but ongoing litigation and the historical inability to generate sustained positive cash flow remain concerns. The stock repurchase program could offer some support, but the overall financial performance and the inherent risks in drug development suggest a "hold" recommendation for a seasoned investor, awaiting clearer signs of sustained profitability and successful commercialization of its pipeline assets.

Keywords

Pharmaceuticals, Diagnostics, Biotechnology, SEC Filing, 10-Q, OPKO Health, NGENLA, Somatrogon, Rayaldee, ModeX Therapeutics, BioReference, Labcorp, Merck, Regeneron, BARDA, Clinical Trials, R&D, Corporate Governance, Financial Results, Q3 2025, Growth Hormone Deficiency, Secondary Hyperparathyroidism, Oncology Diagnostics, EBV Vaccine, Multispecific Antibodies, Stock Repurchase, Convertible Notes